The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | Updates in ALK+ lung cancer: GLASS, ALEX, ALTA-1L and CROWN
WCLC 2021 saw lots of discussion surrounding the treatment of patients with ALK-positive lung cancer. Nir Peled, MD, PhD, Sackler Faculty of Medicine, Tel Aviv University, Israel, shares some of the latest trends and trial data from the ALK-positive field. Prof. Peled discusses the GLASS retrospective study of lorlatinib in previously treated patients with ALK/ROS1+ non-small cell lung cancer (NSCLC), which showed a significant survival benefit for both patient groups and was well tolerated. There is a pattern of next generation ALK tyrosine kinase inhibitor (TKIs) making their way to first-line use. For example, alectinib has shown superior results to crizotinib in untreated ALK+ NSCLC in the ALEX trial (NCT02075840), as did brigatinib in the ALTA-1L trial (NCT02737501). Additionally, the ongoing CROWN study (NCT03052608) is looking into lorlatinib versus crizotinib in first line treatment of ALK+ NSCLC. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
